| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_577821cf81fda3e1088e6ed08bcd136b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_264f4b3f5076536c149ea102bec29be3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_92e348c45f94286dc4323cf6ad1acbca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec3d7a9a543c4214ef75cdabb2d0e04b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1dbd4b0a0608d7e2a5f69c61867df58c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-02 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-473
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-473
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2013-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50e0286f5ad045d7309fa92f4df08630
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18fbebd7a1a11944e22099572692096d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f039ac7e9815558a80e98376c531e069 |
| publicationDate |
2015-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9078895-B2 |
| titleOfInvention |
Method for treating ocular cancer |
| abstract |
It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided. |
| priorityDate |
2006-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |